How to appeal a CareFirst BCBS myasthenia gravis & cidp denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

CareFirst BCBS-specific note: BCBS licensee for Maryland, DC, and northern Virginia (~3.5M members). Operates as non-profit. Appeals jurisdiction depends on policy issue location — MIA (MD), DISB (DC), or SCC Bureau of Insurance (VA). CVS Caremark is the PBM.

What CareFirst BCBS's policy requires for myasthenia gravis & cidp

Cited policy: BCBS Vyvgart Hytrulo (efgartigimod alfa + hyaluronidase) SC for CIDP

Diagnosis of CIDP per EAN/PNS 2021 criteria (definite or probable) confirmed by neuromuscular specialist. ICD-10 G61.81. Documented inadequate response, intolerance, or chronic dependence on standard CIDP therapy (IVIG, corticosteroids, or PLEX). INCAT or I-RODS disability documented. Reauth at 6 mo with disability scoring response.

How CareFirst BCBS denies myasthenia gravis & cidp — and how to counter it

Where CareFirst BCBS pushes back: 1) Must fail IVIG, steroids, AND PLEX before Vyvgart; 2) IVIG-responsive patients should continue IVIG indefinitely; 3) CIDP diagnosis questioned without nerve biopsy.

Counter-arguments that hold up: ADHERE (Allen Lancet Neurol 2024) — Phase 3 Vyvgart Hytrulo SC in CIDP enrolled BOTH IVIG-refractory AND IVIG-responsive patients on chronic IVIG dependence; significant relapse-risk reduction. Supported FDA approval Jun 21, 2024 — label is CIDP, no step-therapy requirement. EAN/PNS 2021 (Van den Bergh JPNS 2021) lists IVIG/steroids/PLEX as PARALLEL first-line, NOT sequential. Chronic IVIG dependence is itself an indication. EAN/PNS 2021 diagnostic criteria do NOT require nerve biopsy — definite/probable based on clinical + electrodiagnostic features (NCS demyelinating: prolonged distal motor latency, conduction velocity slowing, partial conduction block, prolonged F-waves) with supportive CSF cytoalbuminologic dissociation.

What CareFirst BCBS typically denies for myasthenia gravis & cidp

Across CareFirst BCBS's commercial and Medicare books, denials cluster around a small number of patterns. For myasthenia gravis & cidp, expect:

• DC/MD/VA cross-jurisdiction issues
• Step therapy on specialty drugs via CVS Caremark
• Behavioral health network adequacy
• BlueChoice HMO referral denials

Treatments most often denied in this category

These are the myasthenia gravis & cidp treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Soliris (MG)
• Ultomiris (MG)
• Vyvgart IV (MG)
• Vyvgart Hytrulo (MG)
• Rystiggo (MG)
• Zilbrysq (MG)

How to submit the appeal to CareFirst BCBS

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document CareFirst BCBS cited in the denial.
3. File the appeal through CareFirst BCBS's portal (members: https://member.carefirst.com ; providers: https://provider.carefirst.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MD, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See CareFirst BCBS's prior-authorization criteria by drug: CareFirst BCBS PA criteria on ApprovalHelp.